BRIDGING THE GAPS IN CARE OF FAMILIAL HYPERCHOLESTEROLEMIA

Transcription

1 BRIDGING THE GAPS IN CARE OF FAMILIAL HYPERCHOLESTEROLEMIA Co-chairs: Christie Ballantyne, MD and John Chapman, PhD, DSc *** Monday, October 13 th Breakfast and Registration: 7:00am-8:00am Welcome.8:00am-8:25am Focus on FH as the single biggest genetic cause of cardiovascular disease. A look at the progress that has been made since the 2013 FH Global Summit and the work at hand. - Joshua Knowles, MD, PhD and Katherine Wilemon, BS I. Promise to Practice (Opening remarks) 8:25am-8:55am 1. Bridging the gaps in care that exist across the globe through systematic diagnosis, screening, patient engagement, and risk-appropriate treatment - Christie Ballantyne, MD 2. Comments on EAS/HoFH Statements, Genotyping vs. phenotyping - John Chapman, PhD, DSc 1

2 II. The Gap Across the Globe.8:55am-10:40am 1. North America: FH in the U.S. Marina Cuchel, MD, PhD 2. South America (Chile): Ada Cuevas, MD 3. Europe: FH diagnosis and treatment in France - Eric Bruckert, MD, PhD 4. Middle East: FH in Oman Khalid al Rasadi, MD 5. Russia Andrey Susekov, MD 6. Japan Mariko Harada-Shiba, MD, PhD 7. Australia - Gerald Watts, PhD, DSc Break 10:40am-10:50am III. Bridging the Gap: Undiagnosed to Diagnosed 10:55am-12:05pm 1. EMR screening in PCPs in England - Nadeem Qureshi, DM 2. Models of Success in other chronic diseases - Daniel Hommes, MD, PhD 3. FIND FH Initiative - Joshua Knowles, MD, PhD and Kelly Myers, BS Panel discussion: All above speakers Lunch break 12:05pm-1:05pm IV. FH Individual to FH Family: Cascade Screening...1:10pm-2:20pm 1. Reverse cascade screening / Cascade screening - Albert Wiegman, MD, PhD 2

3 2. Genotyping and its implications for the FH family - Zahid Ahmad, MD 3. Strategy of Cascade screening in the U.S. within/without Genotyping (results working group; presenting proposal on behalf of FHF) - Seth Baum, MD Panel Discussion: All above speakers, Mats Eriksson, MD, PhD, Scott Radabaugh, MA, Amy Sturm, MS Break 2:20pm 2:30pm Breakout session.. 2:30pm-3:15pm 3

4 BREAKOUT GROUPS Group 1: Putting guidelines into practice to optimize care for FH Group 2: What tools can we develop to empower Primary Care Providers and Specialists to find FH? Group 3: How can we best leverage technology to find FH patients? Group 4: Patient-centric Advocacy / FH Global Network Group 5: FH Pediatrics Break 3:15pm 3:30pm Reporting Breakout Groups: 3:30pm-4:20pm Wrap-up Session.. 4:20pm-4:45pm *** Gala Reception at University Club.6:30pm 7:30pm Dinner at University Club...7:30pm 9:30pm 4

5 Tuesday, October 14 th Breakfast: 7:00am-8:00am V. Primary to Specialty 8:00am-9:25am 1. Education, Education, Education: Differentiating Between Lifestyle-induced High Cholesterol and Autosomal Dominant Genetic Lipid Disorders In Medical Community (US) James Underberg, MD In Public and Patient Community (Spain) - Rodrigo Alonso Karlezi, MD, PhD 2. The Critical Role of the Primary Care Provider in Diagnosing FH North America - Julie Wood, MD (AAFP) 3. Specialist Perspective on FH Risk and Care Continuum: Stopping the Progression From Genetic Mutation To Vascular Disease - Daniel Rader, MD Panel Discussion: All above speakers VI. Diagnosed to Treated 9:30am-11:45am Part 1: 9:30am 10:15am 1. Guidelines To Practice: A Clear Path to Optimal Care (What are the major differences in the guidelines from different countries? - EAS, NLA, AHA guidelines) Alberico Catapano, MD, PhD 2. Pediatric perspective: When to initiate therapy in children and adolescents and how to maximize long-term compliance Sarah de Ferranti, MD 3. Barriers in optimal care (access, reimbursement) April Kunze, PharmD Break 10:15am 10:25am 5

6 Part 2: 10:30am 11:40am 4. Changing policy: Cost Benefits of FH screening and treatment and health economics - Kees Hovingh, MD, PhD 5. Changing patient engagement: Increasing adherence and patient engagement as part of lifelong management Kyra Bobinet, MD, MPH 6. Strategies for guideline implementation and changing physician behavior Ralph Gonzales, MD Panel Discussion: all above speakers, Anne Goldberg, MD Conclusion and Calls To Action.11:45am-12:30pm Co-chairs: Christie Ballantyne, MD and John Chapman, PhD, DSc Closing reception: 12:30pm-1:30pm 6